Dyne Therapeutics (NASDAQ:DYN) Given New $50.00 Price Target at HC Wainwright

Dyne Therapeutics (NASDAQ:DYN) had its price objective lowered by HC Wainwright from $60.00 to $50.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. lowered their target price on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th. Robert W. Baird set a $30.00 price objective on Dyne Therapeutics in a research report on Monday, December 8th. Royal Bank Of Canada boosted their target price on Dyne Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Sanford C. Bernstein set a $23.00 target price on Dyne Therapeutics in a research note on Tuesday, December 9th. Finally, Morgan Stanley reduced their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $37.00.

Dyne Therapeutics Trading Down 9.6%

DYN opened at $14.60 on Tuesday. Dyne Therapeutics has a one year low of $6.36 and a one year high of $25.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.47 and a quick ratio of 13.47. The business has a 50 day simple moving average of $17.36 and a two-hundred day simple moving average of $17.05. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of -4.12 and a beta of 1.34.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02). Analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. raised its position in Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after buying an additional 14,727,667 shares during the last quarter. Orbis Allan Gray Ltd bought a new stake in shares of Dyne Therapeutics in the fourth quarter worth approximately $93,926,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Dyne Therapeutics during the second quarter valued at approximately $30,378,000. Perceptive Advisors LLC raised its holdings in shares of Dyne Therapeutics by 543.7% during the fourth quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock valued at $68,048,000 after purchasing an additional 2,938,500 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in Dyne Therapeutics by 572.9% during the third quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock valued at $38,119,000 after purchasing an additional 2,565,570 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.